期刊
BIOMEDICAL JOURNAL
卷 38, 期 2, 页码 111-116出版社
ELSEVIER SCIENCE BV
DOI: 10.4103/2319-4170.130923
关键词
5-fluorouracil; anticancer immunity; immunomodulation; immunosuppression; inflammasome; myeloid-derived suppressor cell
资金
- Ligue Nationale contre le Cancer
- Institut National du Cancer
- Association pour la recherche sur le cancer
- Conseil Regional de Bourgogne
- FEDER
- Fondation de France
- Agence Nationale de la Recherche [ANR-13-JSV3-0001-01, ANR-11-LABX-0021]
- Ligue Regionale contre le cancer Comite Grand-Est
- European Community [PCIG10-GA-2011-303719]
5-Flurouracil (5-FU), a pyrimidine analog, was originally designed to prevent tumor cell growth. However, since the identification of its tumor inhibitory activity in 1957, substantial evidence has demonstrated that 5-FU could also harness the host immune system to prevent cancer progression. 5-FU sensitizes tumor cells to Natural Killer (NK) and CD8 T cell-driven cytotoxicity. We have also recently shown that 5-FU could selectively eliminate Myeloid Derived Suppressor Cells (MDSCs), which accumulate during cancer progression and compromise anticancer immune responses. The ability of 5-FU to trigger direct tumor cell death, enhance immune effector cell activation and eliminate immunosuppressive MDSCs explains its capacity to relieve tumor-induced immunosuppression and restore anticancer immune responses. Combination therapies using 5-FU with other chemotherapeutic agents, immunomodulators, or vaccines have further enhanced the clinical benefit of 5-FU. Here, we discuss how the increased understanding of the immune-driven effects of 5-FU prompts the design of relevant cancer chemoimmunotherapy strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据